Endometrial cancer risk with medroxyprogesterone appears to decrease with a greater number of days used per month

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1027, 2004-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risedronate on Two Consecutive Days per Month

By Frampton James E.

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 355-362

Adis International

Access to resources Recommend Favorite

Estrogen replacement therapy appears beneficial for survivors of endometrial cancer

Inpharma, Vol. 1, Iss. 1225, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Medroxyprogesterone is an effective, fertility sparing treatment for endometrial cancer and atypical hyperplasia, but the recurrence rate is considerable

Inpharma, Vol. 1, Iss. 1599, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Consumption of coffee appears to be associated with a reduced risk of liver cancer

Inpharma, Vol. 1, Iss. 1606, 2007-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Is Beta-Blocker Treatment Associated with a Decrease in the Risk of Cancer

Letters in Drug Design & Discovery, Vol. 3, Iss. 9, 2006-11 ,pp. : 653-661

Bentham Science Publishers

Access to resources Recommend Favorite